The federal government\u2019s decision to not provide Novavax\u2019s COVID-19 vaccine this respiratory virus season raises health equity concerns, experts and advocates say, as some Canadians look to the U.S. to get the shot.<\/p>\n
The Public Health Agency of Canada said it won\u2019t provide the protein-based vaccine called Nuvaxovid because the manufacturer required a minimum order that far exceeds last year\u2019s uptake of the vaccine.<\/p>\n
The health agency said 125,000 Nuvaxovid doses were ordered in 2023, but only 5,529 were administered. This fall, it will only supply provinces and territories with the reformulated Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines.<\/p>\n
But some Canadians who say they are immunocompromised and have had adverse reactions to the mRNA vaccines are calling the decision unfair.<\/p>\n","protected":false},"excerpt":{"rendered":"
The federal government\u2019s decision to not provide Novavax\u2019s COVID-19 vaccine this respiratory virus season raises health equity concerns, experts and advocates say, as some Canadians look to the U.S. to get the shot.<\/p>\n
The Public Health Agency of Canada said it won\u2019t provide the protein-based vaccine called Nuvaxovid because the manufacturer required a minimum order that far exceeds last year\u2019s uptake of the vaccine.<\/p>\n
The health agency said 125,000 Nuvaxovid doses were ordered in 2023, but only 5,529 were administered. This fall, it will only supply provinces and territories with the reformulated Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines.<\/p>\n
But some Canadians who say they are immunocompromised and have had adverse reactions to the mRNA vaccines are calling the decision unfair.<\/p>\n